The size of the Plasma Protein Therapeutics Market in the Asia Pacific is currently estimated at USD 4906.77 Million in 2020. It is further forecasted to reach USD 8505.51 Million by 2025, growing at a significant CAGR of 11.63% in the review period.
Recent years have witnessed the emergence of plasma proteins being used in medical applications. The process of fractionating protein from plasma has become more efficient and cost-saving, with the technology advancements adding a significant boost to the market.
Plasma is a fluid rich with proteins and plays an important role in providing immunity and blood clotting. Extracting the plasma proteins can help carry out medical therapies for immune deficiencies, autoimmune, bleeding, and neurological disorders. These therapies treat the medical conditions by replacing the missing or deficient proteins in plasma. Through plasma protein therapies, the treatment involves the infusion or injection of biological medicine to cure life-threatening chronic and genetic diseases.
The introduction of new plasma-derived therapies in the market is the key driving force for the market, along with a host of other drivers that include increasing prevalence of life-threatening diseases involving neurological or immune systems like chronic inflammatory demyelinating polyneuropathy (CIPD), Idiopathic thrombocytopenic purpura (ITP) and other diseases such as Rabies, Hepatitis A&B, Tetanus and varicella.
However, there are few hurdles the market must overcome to sustain in the future which including reimbursement issues, stringent regulatory policies, and complexities in manufacturing.
This research report on the Asia Pacific Plasma Protein Therapeutics Market has been segmented and sub-segmented into the following categories:
By Type:
By Application:
By Country:
Companies dominating the APAC Plasma Protein Therapeutics Market profiled in this report are Grifols, CSL Behring, Baxter, Krdrion, China Biologics, Octapharma, Chendu Inst, and Shire Plc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Immunoglobulins
5.1.2 Albumin
5.1.3 Coagulation Factors
5.1.4 Alpha-1 proteinase inhibitor
5.1.5 Others
5.2 By Application
5.2.1 Hemophilia
5.2.2 Primary Immunodeficiency Disorder
5.2.3 Idiopathic Thrombocytopenic Purpura
5.2.4 Secondary Immunodeficiency
5.2.5 others
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 CSL Behring
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Baxter
8.3 Biotest
8.4 China Biologics
8.5 Grifols
8.6 Kedrion
8.7 Octapharma
8.8 Shire Plc.
8.9 Chengdu Inst.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
